利索-全球专利检索

  1. 登录
  2. 注册
发明公开
CN103562218A 显性负性HSP110突变体及其在预测和治疗癌症中的用途 有权

显性负性HSP110突变体及其在预测和治疗癌症中的用途
摘要：
本发明涉及缺乏其底物结合域的突变的热休克蛋白110(HSP110)，其不表现出其伴侣活性和／或不能结合热休克蛋白70(HSP70)和／或热休克蛋白27(HSP27)，但是它能够结合野生型HSP110。这种突变的热休克蛋白110可(i)用于预测患有癌症，更特别是患有易于具有微卫星不稳定性(MSI)表型的癌症，如结肠直肠癌(CRC)的患者的生存率和／或对治疗的反应的方法，及(ii)用于治疗癌症。
摘要（英）：

The present invention relates to a mutated heat-shock protein 110 (HSP110) lacking its substrate binding domain, which does not exhibit its chaperone activity and/or is not capable of binding to heat-shock protein 70 (HSP70) and/or to heat-shock protein 27 (HSP27), but which is capable of binding to a wild-type HSP110. Such a mutated heat- shock protein 110 can be used (i) in methods for prognosing survival and/or the response to a treatment of a patient suffering from a cancer, more particularly from a cancer liable to have a microsatellite instability (MSI) phenotype, such as colorectal cancer (CRC), and (ii) for treating cancers.

公开/授权文献
0/0